Jefferies Financial Group Inc. Invests $907,000 in Amneal Pharmaceuticals, Inc. $AMRX

Jefferies Financial Group Inc. acquired a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 71,992 shares of the company’s stock, valued at approximately $907,000.

Other hedge funds have also modified their holdings of the company. Comerica Bank grew its holdings in shares of Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after buying an additional 1,957 shares in the last quarter. Spire Wealth Management grew its holdings in shares of Amneal Pharmaceuticals by 66.6% during the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after buying an additional 1,023 shares in the last quarter. Focus Partners Wealth bought a new position in shares of Amneal Pharmaceuticals during the third quarter worth about $42,000. Advisory Services Network LLC bought a new position in shares of Amneal Pharmaceuticals during the third quarter worth about $50,000. Finally, Strs Ohio bought a new position in shares of Amneal Pharmaceuticals during the fourth quarter worth about $52,000. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Stock Up 1.7%

AMRX stock opened at $13.17 on Friday. The business has a 50 day moving average price of $12.62 and a two-hundred day moving average price of $12.92. The company has a market cap of $4.20 billion, a price-to-earnings ratio of 34.66 and a beta of 1.32. Amneal Pharmaceuticals, Inc. has a twelve month low of $7.07 and a twelve month high of $15.42.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. The firm had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%. On average, equities research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the transaction, the director directly owned 93,660 shares in the company, valued at $1,211,960.40. This trade represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 17.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently issued reports on AMRX. Barclays increased their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. Truist Financial increased their price objective on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. UBS Group began coverage on Amneal Pharmaceuticals in a report on Friday, April 17th. They set a “buy” rating and a $19.00 price objective for the company. Finally, Weiss Ratings downgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.17.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.